Loading clinical trials...
Loading clinical trials...
A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2), in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Conditions
Interventions
Placebo
SIM
Locations
68
United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
Southern California Liver Centers
Coronado, California, United States
University of California, San Diego (UCSD)
San Diego, California, United States
University of California San Francisco (UCSF)
San Francisco, California, United States
University of Colorado
Aurora, Colorado, United States
Miami Veterans Administration Healthcare System
Miami, Florida, United States
Start Date
December 5, 2012
Primary Completion Date
August 2, 2016
Completion Date
December 29, 2016
Last Updated
March 27, 2019
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions